Cipla signs deal with Salix

Under the agreement, Cipla has granted US-based Salix Pharmaceuticals exclusive rights under certain patent applications in the ‘Rifaximin Complexes’ patent family controlled by Cipla


(Photo Courtesy:

The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa.

Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the ‘Rifaximin Complexes' patent rights.

Salix also will pay a royalty on net sales of products covered by the ‘Rifaximin Complexes' patents licensed to Salix.

Last year, Cipla announced the expansion of its existing collaboration with MEDA by granting global commercialization rights for a proprietary combination nasal spray product (fluticasone and azelastine), Dymista.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email